Comparative Clinical Pharmacokinetics of Dipeptidyl Peptidase-4 Inhibitors

被引：0
作者：
Larry K. Golightly
Caitlin C. Drayna
Michael T. McDermott
机构：
[1] University of Colorado Hospital,Division of Endocrinology, Metabolism, and Diabetes
[2] University of Colorado Hospital Center for Drug Information,Medication Use Evaluation/Adverse Drug Reaction Coordinator
[3] Education,undefined
[4] and Evaluation,undefined
[5] University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences,undefined
[6] University of Colorado School of Medicine,undefined
[7] University of Colorado Hospital,undefined
[8] Anschutz Medical Campus Box A-003,undefined
[9] Health Sciences Library/Center for Drug Information,undefined
[10] Education,undefined
[11] and Evaluation,undefined
来源：
Clinical Pharmacokinetics | 2012年 / 51卷 / 8期
关键词：
Sitagliptin; Vildagliptin; Severe Renal Impairment; Saxagliptin; Linagliptin;
D O I：
10.1007/BF03261927
中图分类号：
学科分类号：
摘要：
Dipeptidyl peptidase-4 (DPP-4) inhibitors collectively comprise a presently unique form of disease management for persons with type 2 diabetes mellitus. The aim of this review is to compare the clinical pharmacokinetics of available DPP-4 inhibitors (alogliptin, linagliptin, saxagliptin, sitagliptin and vildagliptin) for the purpose of identifying potential selection preferences according to individual patient variables and co-morbidities.
引用
收藏
页码：501 / 514
页数：13
相关论文
共 371 条
[21]  
Lund A.(2011)Effects of chronic administration of alogliptin on the development of diabetes and β-cell function in high fat diet/streptozotocin diabetic mice Diabetes Obes Metab 13 337-47
[22]  
Holst J.J.(2011)Sitagliptin lowers glucagon and improves tolerance in prediabetic SHROB rats Exp Biol Med 236 309-14
[23]  
Krarup T.(2010)Dipeptidyl peptidase-4 inhibitors administered in combination with metformin result in an additive increase in the plasma concentration of active GLP-1 Clin Pharmacol Ther 88 801-8
[24]  
Knop F.K.(2011)Dipeptidyl peptidase IV inhibitor sitagliptin reduces local inflammation in adipose tissue and in pancreatic islets of obese mice Am J Physiol Endocrinol Metab 300 E410-21
[25]  
Hare K.J.(2011)Diet-induced adipose tissue inflammation and liver steatosis are prevented by DPP-4 inhibition in diabetic mice Diabetes 60 1246-57
[26]  
Vilsbøll T.(2010)Combination therapy with nateglinide and vildagliptin improves postprandial metabolic derangements in Zucker fatty rats Horm Metab Res 42 731-5
[27]  
Asmar M.(2006)Vildagliptin therapy reduces intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes Diabetologia 49 2047-57
[28]  
Flint A.(2011)Effect of enhanced glycemic control with saxagliptin on endothelial nitric oxide release and CD40 levels in obese rats J Atheroscler Thromb 18 774-83
[29]  
Raben A.(2011)Selective inhibition of dipeptidyl peptidase 4 by targeting a substrate-specific secondary binding site Biol Chem 392 223-31
[30]  
Astrup A.(2010)Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation Health Technol Assess 14 1-248
12345678910